ATE548387T1 - Neue monoklonale schilddrüsen-stimulierende oder -blockierende antikörper, korrespondierende peptidesquenzen ihrer variablen regionen, und deren verwendung in diagnostik, präventiver und therapeutischer medizin - Google Patents
Neue monoklonale schilddrüsen-stimulierende oder -blockierende antikörper, korrespondierende peptidesquenzen ihrer variablen regionen, und deren verwendung in diagnostik, präventiver und therapeutischer medizinInfo
- Publication number
- ATE548387T1 ATE548387T1 AT04015239T AT04015239T ATE548387T1 AT E548387 T1 ATE548387 T1 AT E548387T1 AT 04015239 T AT04015239 T AT 04015239T AT 04015239 T AT04015239 T AT 04015239T AT E548387 T1 ATE548387 T1 AT E548387T1
- Authority
- AT
- Austria
- Prior art keywords
- variable regions
- thyroid stimulating
- autoantibodies
- fragments
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rehabilitation Therapy (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04015239A EP1612224B1 (de) | 2004-06-29 | 2004-06-29 | Neue monoklonale Schilddrüsen-stimulierende oder -blockierende Antikörper, korrespondierende Peptidesquenzen ihrer variablen Regionen, und deren Verwendung in Diagnostik, präventiver und therapeutischer Medizin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE548387T1 true ATE548387T1 (de) | 2012-03-15 |
Family
ID=34925537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04015239T ATE548387T1 (de) | 2004-06-29 | 2004-06-29 | Neue monoklonale schilddrüsen-stimulierende oder -blockierende antikörper, korrespondierende peptidesquenzen ihrer variablen regionen, und deren verwendung in diagnostik, präventiver und therapeutischer medizin |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8029790B2 (de) |
| EP (1) | EP1612224B1 (de) |
| JP (1) | JP4980901B2 (de) |
| AT (1) | ATE548387T1 (de) |
| ES (1) | ES2382627T3 (de) |
| WO (1) | WO2006002774A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8350012B2 (en) | 2007-01-25 | 2013-01-08 | Cedars-Sinai Medical Center | Inverse agonist monoclonal antibody that suppresses thyrotropin receptor constitutive activity |
| JP5676316B2 (ja) * | 2010-03-09 | 2015-02-25 | 富士フイルム株式会社 | ヒトtsh及び犬tshに対する抗体 |
| RU2012153241A (ru) * | 2010-05-11 | 2014-06-20 | Авео Фармасьютикалз, Инк. | Антитела к fgfr2 |
| US8785603B2 (en) | 2011-05-20 | 2014-07-22 | Siemens Healthcare Diagnostics Inc. | Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof |
| CN102735850A (zh) * | 2012-07-16 | 2012-10-17 | 天津医科大学总医院 | 定量检测人血清促甲状腺素受体抗体的酶联免疫分析试剂盒及检测方法 |
| CN105189558A (zh) * | 2013-05-02 | 2015-12-23 | 豪夫迈·罗氏有限公司 | 无岩藻糖基化CD20抗体与CD79b抗体-药物缀合物的组合疗法 |
| EP3548055A4 (de) | 2016-12-02 | 2020-08-19 | University of Southern California | Synthetische immunrezeptoren und verfahren zur verwendung davon |
| CN111690680A (zh) * | 2020-06-10 | 2020-09-22 | 成都和同易创生物科技有限公司 | Tbab人源单克隆抗体重组载体、重组抗体及其制备方法 |
| CN111647624A (zh) * | 2020-06-10 | 2020-09-11 | 成都和同易创生物科技有限公司 | Tsab人源单克隆抗体重组载体、重组抗体及其制备方法 |
| CN120230208A (zh) * | 2024-08-07 | 2025-07-01 | 上海交通大学医学院附属第九人民医院 | 一组sh23同源簇全人源tsh受体阻断性单克隆抗体及其制备方法和应用 |
| CN121027545B (zh) * | 2025-10-31 | 2026-02-03 | 华中科技大学同济医学院附属协和医院 | 甲状腺相关眼病的负离子代谢标志物、产品及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5707622A (en) * | 1994-03-03 | 1998-01-13 | Genentech, Inc. | Methods for treating ulcerative colitis |
| DE19907094C1 (de) * | 1999-02-19 | 2000-04-13 | Brahms Diagnostica Gmbh | Verwendung von blockierenden Anti-TSH-Rezeptor-Antikörpern bei der Therapie von Hyperthyreosen sowie monoklonale Antikörper für eine solche Verwendung |
| EP1169352A4 (de) * | 1999-04-14 | 2005-05-04 | Smithkline Beecham Corp | Antikörper gegen den erythropoietin-rezeptor |
| DE10035706C2 (de) | 2000-07-21 | 2002-11-07 | Brahms Ag | Verfahren zur selektiven Bestimmung von blockierenden Autoantikörpern gegen den TSH-Rezeptor |
| ES2736165T3 (es) * | 2001-08-23 | 2019-12-26 | Rsr Ltd | Regiones epítopo de un receptor de tirotropina (TSH), sus usos y anticuerpos para las mismas |
| AU2003244817B2 (en) * | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| DE50306067D1 (de) | 2002-11-26 | 2007-02-01 | Brahms Ag | Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern |
| WO2004050708A2 (en) * | 2002-11-29 | 2004-06-17 | Rsr Limited | Antibody for the thyrotropin receptor and uses thereof |
-
2004
- 2004-06-29 ES ES04015239T patent/ES2382627T3/es not_active Expired - Lifetime
- 2004-06-29 EP EP04015239A patent/EP1612224B1/de not_active Expired - Lifetime
- 2004-06-29 AT AT04015239T patent/ATE548387T1/de active
-
2005
- 2005-06-16 JP JP2007518492A patent/JP4980901B2/ja not_active Expired - Fee Related
- 2005-06-16 WO PCT/EP2005/006500 patent/WO2006002774A1/en not_active Ceased
- 2005-06-16 US US11/570,951 patent/US8029790B2/en active Active
-
2011
- 2011-07-12 US US13/181,170 patent/US9040670B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008509887A (ja) | 2008-04-03 |
| EP1612224B1 (de) | 2012-03-07 |
| ES2382627T3 (es) | 2012-06-12 |
| EP1612224A1 (de) | 2006-01-04 |
| US9040670B2 (en) | 2015-05-26 |
| US20120253019A1 (en) | 2012-10-04 |
| WO2006002774A1 (en) | 2006-01-12 |
| US8029790B2 (en) | 2011-10-04 |
| US20090012268A1 (en) | 2009-01-08 |
| JP4980901B2 (ja) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ritter et al. | Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33 | |
| NO20210499A1 (no) | Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning | |
| HRP20191341T1 (hr) | Protutijela koja vežu ljudski cgrp receptor | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| JP2009100745A5 (de) | ||
| EA012079B3 (ru) | Моноклональное антитело к рецептору инсулиноподобного фактора роста i (igf-i) и способы его применения | |
| RU2009108147A (ru) | Иммуноглобулины | |
| JP2013523190A5 (de) | ||
| JP2004531217A5 (de) | ||
| WO1996023071A3 (en) | MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY | |
| RU2018137110A (ru) | Антитела против psma и их применение | |
| JP2016510319A (ja) | 多価結合タンパク質組成物 | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| MY145703A (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors | |
| ATE548387T1 (de) | Neue monoklonale schilddrüsen-stimulierende oder -blockierende antikörper, korrespondierende peptidesquenzen ihrer variablen regionen, und deren verwendung in diagnostik, präventiver und therapeutischer medizin | |
| JP2007529196A5 (de) | ||
| CN110461874B (zh) | 抗gitr抗体、其抗原结合片段及其医药用途 | |
| DE69535562D1 (de) | Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden | |
| TW202216773A (zh) | 識別分選蛋白(sortilin)的抗體 | |
| CN113227148A (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| CN115298216A (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
| HRP20120975T1 (hr) | Terapeutska upotreba anti-cs1 antitijela | |
| GB2600273A (en) | Antibody to leptin receptor | |
| TW201915016A (zh) | 單株抗體或其抗原結合片段及其用途 | |
| RU2024118344A (ru) | Антитело или его антигенсвязывающий фрагмент |